4th Treg Directed Therapies Summit

Memo

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy.The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally.With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:Optimize stable expansion of Tregs to maintain function to elicit durable responsesDecode Treg interactions to optimize the mechanism of actions and inform biomarker developmentRationalize activation, formulation and delivery strategy to induce antigen specific toleranceSupercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy200+ senior level drug developers will be uniting in May to chase the holy grail of Treg-directed therapies. Don't miss your chance to network with the avant-garde to inform your Treg pipeline and capitalize on the shared knowledge of this collaborative community.URLs:Brochure: https://go.evvnt.com/991160-0?pid=5569Tickets: https://go.evvnt.com/991160-2?pid=5569Prices:Drug Developers - Conference + Focus Day (Earlybird rates available): USD 4946.0,Drug Developers - Conference + Only (Earlybird rates available): USD 2999.0,Service Providers - Conference + Focus Day (Earlybird rates available): USD 5846.0,Service Providers - Conference Only (Earlybird rates available): USD 3599.0,Academic Pricing - Conference + Focus Day (Earlybird rates available): USD 4246.0,Academic Pricing - Conference Only (Earlybird rates available): USD 2599.0Speakers: Richard Ransohof, Co-Founder and CMO Abata and Venture Partner, Third Rock Ventures, Thomas Wickham, CSO, GentiBio, Jonathan Zalevsky, Chief Research and Development Officer, Nektar Therapeutics, Kei Kishimoto, CSO, Selecta Biosciences, Stanley H. Appel MD, Chair and Scientific Advisory Board, Houston Methodist Research Institute / Coya Therapeutics, Melanie A. Kleinschek, DVM, PhD CSO, TRexBio, Khaled Ali, Director of Immunoregulation, GlaxoSmithKline, Anubhav Mathur, Director, Clinical Research, Gilead Sciences, Michael Rosenblum, MC, PhD Professor of Dermatology, Vice Chair of Research, Department of Dermatology, UCSF, Marc MartinezLlordella, Co-Founder and VP Biology, Quell Therapeutics, Matthew M Seavey, Ph.D, MBA VP of Research, Heat Biologics, Inc., Kristine M Swiderek, CSO, Mozart Therapeutics Inc., Jeffrey Greve, CSO, Kyverna Therapeutics, Thomas Malek, Professor, University of Miami, Lenny Dragone, CMO, Sonoma, John Cho, Director, Immunobiology, KSQ Therapeutics, Anne S. De Groot MD, CEO/CSO, EpiVax, Inc., Maria Amann, PhD Senior Principal Scientist, Roche, Stanley H. Appel MD, Chair and Scientific Advisory Board, Houston Methodist Research Institute / Coya Therapeutics, Brendan J Classon, PhD Executive VP, Research and Development, Parvus Therapeutics, Jonathan Davis, Ph.D. VP of Innovation and Strategy, Invenra, Inc., Dana Gilmore, Senior Scientist, TCR2, Haining Huang, CSO, Cytimm Therapeutics, David Hafler, Professor and Chair, Yale School of Medicine, David Klatzmann, Professor, Sorbonne University, Amy Rosenberg, Senior Director of Immunology and Protein Therapeutics, EpiVax, Inc, Wayne William, Hancock Professor of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and University of Pennsylvania, Wanjun Chen, Senior Investigator, NIH NIDCR, Garrison Fathman, Professor, Stanford University School of Medicine, Leonardo M.R. Ferreira, Assistant Professor of Microbiology and Immunology Medical, University of South Carolina, Denise L Faustman, MD, PhD Associate Professor, Harvard, Jens Humrich M.D., Consultant and Senior Clinician Scientist, Rheumatology, University Hospital Schleswig-Holstein, Louis-Marie Charbonnier, Assistant Professor, Harvard Medical School and Boston Children's Hospital, Everett Meyer, Assistant Professor, Stanford UniversityDate and Time: On Tuesday May 17, 2022 at 9:00 am (ends Thursday May 19, 2022 at 5:30 pm)Venue Details: Embassy Suites by Hilton Boston at Logan Airport, 207 Porter Street, Boston, Massachusetts, 02128, United States